Welcome to our dedicated page for Alpha Tau Medical SEC filings (Ticker: DRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alpha Tau Medical Ltd. filings document the company's foreign-issuer current reports for Alpha DaRT clinical and regulatory updates. Recent Form 6-K reports furnish press releases and presentations covering studies in recurrent glioblastoma, recurrent cutaneous squamous cell carcinoma, pancreatic cancer, and head and neck cancer.
The filings describe trial enrollment, interim clinical data, safety observations, FDA device-related matters, conference presentations and company presentations furnished as exhibits. They also identify the company's Form 20-F reporting status and the treatment of furnished information under the Securities Exchange Act.
Alpha Tau Medical Ltd. reported positive clinical data from a study combining its Alpha DaRT® alpha‑radiation therapy with pembrolizumab in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma.
Among nine evaluable patients, the combination produced a 100% objective response rate, with four complete and five partial responses, compared with historical pembrolizumab monotherapy benchmarks of about 19% objective response. Median overall survival was 18.2 months and median progression‑free survival was 5.4 months, which the company states compare favorably with historical pembrolizumab figures of 12.3 and 3.2 months, respectively.
No Alpha DaRT‑associated serious adverse events were observed; the only two Alpha DaRT‑associated events were Grade 1 (mild). The single‑arm study, designed to enroll up to 48 patients using a Simon two‑stage adaptive design, met its pre‑specified success criterion once more than six patients responded, and recruitment concluded after 11 patients.
Alpha Tau Medical Ltd. reports the first successful treatment of an immunocompromised patient with recurrent cutaneous squamous cell carcinoma (cSCC) using its Alpha DaRT therapy in the ADMIRE clinical study at Banner MD Anderson Cancer Center in Gilbert, Arizona.
ADMIRE is a prospective, multicenter, open-label, single-arm study evaluating intratumoral Alpha DaRT in immunocompromised patients with recurrent cSCC. It is designed to enroll up to 28 patients at up to 8 U.S. sites, each with a single lesion up to 7 cm. Eligible patients are immunocompromised due to causes such as solid organ transplantation, hematologic malignancy, or chronic immunosuppressive therapy. The primary endpoint is objective response rate per RECIST v1.1, with secondary endpoints including progression-free survival, overall survival, and local control assessed over twelve months.
Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi reported same-day share transactions involving the company’s Ordinary Shares. He exercised 2,270 shares at a price of $2.98 per share and sold 2,270 shares in an open-market sale at $14.0011 per share. Following these transactions, he directly held 90,180 Ordinary Shares.
Alpha Tau Medical Ltd. files a Form 144 notice for the proposed sale of 20,000 ordinary shares acquired upon exercise of employee stock options on 07/06/2026, with cash payment upon exercise. The filing also lists recent sales by the holder between 06/23/2026 and 07/02/2026, including multiple transactions totaling several blocks of ordinary shares.
Alpha Tau Medical Ltd. Chief Financial Officer Raphi Levy executed an exercise-and-sell transaction in company Ordinary Shares. He exercised 17,873 shares at $2.98 per share and then sold 17,873 shares in an open-market sale at an average price of $13.0027 per share on July 2, 2026.
Following these transactions, Levy directly holds 90,180 Ordinary Shares. The pattern shows option exercise to acquire shares and a same-day sale of an equivalent number of shares, while maintaining a substantial remaining equity position.
Alpha Tau Medical Ltd. Chief Financial Officer Raphi Levy reported an exercise-and-sale transaction in Ordinary Shares. Levy sold 2,127 shares in an open-market transaction at an average price of $13.0189 per share and reported direct ownership of 90,180 shares immediately afterward. The filing also shows a corresponding M-code transaction for 2,127 shares at $2.98 per share classified as a derivative exercise or conversion, indicating these shares were acquired through an option exercise before being sold.
Levy Raphi submitted a Form 144 notice to sell 20,000 Ordinary Shares of Alpha Tau Medical Ltd. acquired upon exercise of employee stock options, scheduled 07/01/2026 with cash payment upon exercise. The filing lists prior dispositions in June 2026: 17,500 shares on 06/23/2026, 20,000 shares on 06/25/2026, and 20,000 shares on 06/30/2026, each shown with gross proceeds in local currency.
Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi sold 20,000 Ordinary Shares in an open-market transaction. The shares were sold at an average price of $12.0022 per share. After this sale, Raphi directly holds 90,180 Ordinary Shares of Alpha Tau Medical.
Alpha Tau Medical Ltd. reported insider sales under a Form 144: two dispositions of ordinary shares totaling 37,500 shares in June 2026. The filing also records 65,750 shares issued on 04/01/2023 upon RSU vesting.
Alpha Tau Medical Ltd. Chief Financial Officer Raphi Levy reported open-market sales of 20,000 Ordinary Shares on June 25, 2026. The shares were sold in two transactions at a price of about $11.0002 per share. These transactions reflect a net reduction in his directly held shares.